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Imaging, Diagnosis, Prognosis
Gene Expression Signature–Based Prognostic Risk Score
in Gastric Cancer
Jae Yong Cho1,4, Jae Yun Lim1,4, Jae Ho Cheong1,5, Yun-Yong Park1, Se-Lyun Yoon7, Soo Mi Kim1,9,
Sang-Bae Kim1, Hoguen Kim6, Soon Won Hong6, Young Nyun Park6, Sung Hoon Noh5,
Eun Sung Park1, In-Sun Chu8, Waun Ki Hong2, Jaffer A. Ajani3, and Ju-Seog Lee1
Abstract
Purpose:Despite continual efforts to develop a prognostic model of gastric cancer by using clinical and
pathologic parameters, a clinical test that can discriminate patients with good outcomes from those with
poor outcomes after gastric cancer surgery has not been established. We aim to develop practical
biomarker-based risk score that can predict relapse of gastric cancer after surgical treatment.
Experimental Design: Microarray technologies were used to generate and analyze gene expression
profiling data from 65 gastric cancer patients to identify biomarker genes associated with relapse. The
association of expression patterns of identified genes with relapse and overall survival was validated in
independent gastric cancer patients.
Results:We uncovered two subgroups of gastric cancer that were strongly associated with the prognosis.
For the easy translation of our findings into practice, we developed a scoring system based on the
expression of six genes that predicted the likelihood of relapse after curative resection. In multivariate
analysis, the risk score was an independent predictor of relapse in a cohort of 96 patients. We were able to
validate the robustness of the six-gene signature in an additional independent cohort.
Conclusions: The risk score derived from the six-gene set successfully prognosticated the relapse of
gastric cancer patients after gastrectomy. Clin Cancer Res; 17(7); 1850–7. 2011 AACR.
Introduction
Gastric cancer is the second leading cause of cancer-
related death in the world (1). Surgery remains the gold
standard in the treatment of gastric cancer (2, 3). In the
United States, however, only a small fraction of patients
with gastric cancer who undergo curative resection have
early-stage disease, and the prognosis for patients with
more advanced stage (II or III) remains poor because of
the high rate of relapse after gastrectomy (4, 5). Preo-
perative staging techniques, including laparoscopy and
noninvasive imaging systems (i.e., endoscopic ultrasono-
graphy and positron emission tomography), have a rela-
tively low sensitivity for discriminating patients with
favorable clinical biology versus poor clinical biology
(6). Moreover, the outcomes of patients considered to
have a similar clinical or pathologic stage remain unpre-
dictable, especially when patients are treated similarly.
For example, not all patients with stage III tumor survive 5
years even after successful curative resection (7, 8), and
the outcomes remain uneven whether or not preoperative
or postoperative therapy is administered. This inherent
clinical heterogeneity is most likely due to the diverse
molecular profile of gastric cancer. Thus, identifying the
diversity in the molecular profile of gastric cancer that
governs the clinical behavior of tumors could lead to new
and more effective clinical strategies. Microarray technol-
ogies have been successfully used to predict clinical out-
comes and survival, as well as classify different types of
cancer (9–13). Recent studies in gastric cancer have iden-
tified genes that differ according to histologic factors and
age, as well as those for gastric cancer prognosis predic-
tion (14–16). However, these studies have failed to create
molecular prognostic tests that could be practical for
gastric cancer patients.
In the present study, we characterized tumor transcrip-
tome at the systems level to identify potential markers that
could be used to divide patients into distinct subclasses that
have not been recognized by current staging system.
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Materials and Methods
Patients and samples
Tumor specimens and clinical data from 213 gastric
cancer patients undergoing gastrectomy as a primary treat-
ment option were obtained from Yonsei University Sever-
ance Hospital, Seoul, Korea. Sixty-five surgically removed
frozen gastric adenocarcinoma tissues, with 19 normal
surrounding tissue samples, from gastric cancer patients
were used formicroarray experiments [Yonsei gastric cancer
(YGC) cohort]. In addition, 6 frozen tissue samples from
gastrointestinal stromal tumor (GIST) patients were
included in the microarray experiments as reference for
distinct tumors resided in gastric tissues. To validate gene
expression patterns found by microarray analysis, quanti-
tative reverse transcriptase PCR (qRT-PCR) experiments
were done with RNA from 96 formalin-fixed, paraffin-
embedded (FFPE) tissues from a separate gastric adeno-
carcinoma patient group from Yonsei Gangnam Severance
Hospital (GSH1 cohort). For validation of risk score, FFPE
tissues of independent patient group from Yonsei Gang-
nam Severance Hospital (GSH2 cohort, n ¼ 52) were used
for qRT-PCR. Tissue specimens used in microarray and
qRT-PCR were obtained from the surgical specimens. All
samples were collected after obtaining written informed
consent from patients, and the study was approved by the
Institutional Review Board of The University of Texas M. D.
Anderson Cancer Center (Houston, TX), the Yonsei Uni-
versity Severance Hospital (Seoul, Korea), and Yonsei
Gangnam Severance Hospital (Seoul, Korea). Clinical data
also were obtained retrospectively. All of the experiments
and analyses were done in the Department of Systems
Biology at M. D. Anderson Cancer Center.
Experimental procedures for microarray
Total RNA was extracted from the fresh-frozen tissues
by using a mirVana RNA Isolation labeling kit (Ambion,
Inc.). Five hundred nanograms of total RNA was used for
labeling and hybridization, according to the man-
ufacturer’s protocols (Illumina). The microarray data
were normalized using the quantile normalization
method in the LIMMA (Linear Models for Microarray
Data) package in the R language environment (17).
The expression level of each gene was transformed into
a log2 base before further analysis. Primary microarray
data are available in NCBI’s GEO (Gene Expression
Omnibus) database (http://www.ncbi.nlm.nih.gov/geo/;
microarray platform, GPL6884; microarray data, accession
number GSE13861).
Statistical analysis of microarray data
BRB-ArrayTools were primarily used for all statistical
analysis (18, 19). Gene expression differences were con-
sidered statistically significant if the P value was less than
0.001. Cluster analysis was done with Cluster and Treeview
(20). Kaplan–Meier plots and the log-rank test were used to
estimate patient prognosis. Multivariate Cox proportional
hazards regression analysis was used to evaluate indepen-
dent prognostic factors associated with survival, and gene
signature, tumor stage, and pathologic characteristics were
used as covariates. A P value of less than 0.05 was con-
sidered to indicate statistical significance, and all tests were
2-tailed.
Selection of genes for qRT-PCR assay and
experimental procedures
To select the candidate genes during the course of valida-
tion experiments, we used receiver operating characteristic
(ROC) curves from censored relapse-free survival (RFS)
data using the nearest neighbor estimation method, with
a cutoff value of 36 months and under the curve (AUC)
were calculated with 95% CIs (21). First ROC models were
constructed by using gene expression data frommicroarray
experiments. From 2,755 gene features identified from
microarray experiments, top 27 genes with highest AUC
values (14 genes) or lowest AUC values (13 genes) were
selected for validation with qRT-PCR experiments in the
GSH1 cohort. Using qRT-PCR–based gene expression data
from GSH1 cohort, we constructed second ROC curves to
further select genes with AUCs of more than 0.55 as risk
genes and less than 0.45 as protective genes. Of 27 candi-
date genes, only 6 genes were within the range of selection
cutoff.
Total RNA was extracted from the FFPE sections accord-
ing to the manufacturer’s instruction manual (RecoverAll
Total Nucleic Acid Isolation; Ambion, Inc.). Real-time RT-
PCR amplification was done using the 7900HT Fast Real-
Time PCR System with a 384-well block module (Applied
Biosystems). Cycling conditions were 45C for 10 minutes
and 95C for 10 minutes, followed by 40 cycles of 95C for
15 seconds and 60C for 60 seconds. Relative amounts of
mRNA were calculated from the threshold cycle (Ct) num-
ber using expression of cyclophilin A (PPIA) as an endo-
genous control. All PCR experiments were duplicated and
the values averaged.
Translational Relevance
Gastric cancer is the second leading cause of cancer-
related death in the world, and prognosis is difficult to
predict for individual patients. Most of gastric cancer
patients receive similar treatments, typically surgery
followed by chemotherapy because there are no reliable
biomarkers to optimize therapy. Our study identified
the prognostic gene expression signatures and limited
number of prognostic biomarkers. We developed a
score based on these 6 genes which significantly asso-
ciated with survival and early relapse. This method
requires the determination of only 6 genes by using
simple reverse transcriptase PCR technology and easily
accessible paraffin-embedded tissues, which are routi-
nely acquired at diagnosis. This will open up new
opportunities to optimize treatment of gastric cancer
patients according to molecular subtypes of tumors.
Novel Prognostic Risk Score in Gastric Cancer
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Development of 6-gene risk scoring system
To generate a risk score with 6 genes, we adopted a
previously established strategy by using the Cox regression
coefficient of each gene (22, 23). The risk score of each
patient was derived from sum of multiplication of refer-
ence-normalized expression level of the gene by its
corresponding coefficient: Risk score ¼ (0.097  CTNNB1
value) þ (0.141  EXOCS3 value) þ (0.148  TOP2A
value) þ (0.0898  LBA1 value) þ (0.0985  CCL5
value) þ (0.0618  LZTR1 value). GSH1 patients were
dichotomized into both a high-risk group and a low-risk
group, using the 50th percentile (median) cutoff of the risk
score as the threshold value. Both the coefficient and the
threshold value derived from the GSH1 cohort were
directly applied to the gene expression data from the
exploration data set (YGC cohort) and an independent
test sets (GSH2 patient cohorts).
Results
Two major subclasses revealed by hierarchical
clustering of gene expression patterns are highly
associated with prognosis
We applied hierarchical clustering analysis to gene
expression data from 65 human primary tumor tissue
samples (YGC cohort in Table 1) and 6 GIST tissue
samples. Unsupervised clustering revealed 3 distinctive
subtypes with clear differences in overall gene expression
patterns (Fig. 1A). Most of the gastric cancer tissues were
subdivided into 1 of 2 subgroups (C1 and C2). Intrigu-
ingly, a few gastric cancer tumors (C3) were coclustered
with the GIST tissues, indicating that a small percentage of
gastric cancers may acquire sarcomatoid features during
progression. When clinical relevance was examined, RFS
(systemic) was found to differ significantly between the
2 major clusters (C1 and C2). Kaplan–Meier plots and log-
rank tests indicated that C2 patients had a significantly
better RFS than C1 or C3 patients (P ¼ 0.001 by the log-
rank test; Fig. 1B). When only patients with stage III tumors
were considered for analysis, the differences in prognosis
between C1 and C2 patients were still significant (P ¼
0.005 by the log-rank test; Fig. 1C), indicating that the
molecular features of these tumors reflected in gene expres-
sion patterns might be strong independent predictors of
clinical outcomes. Because the number of gastric cancer
patients in group C3 was too small (n ¼ 5), these patients
were removed from further analysis.
Prognostic gene expression signature in gastric
cancer
Because the C1 subgroup was strongly associated with
poor prognosis, we next sought to identify genes whose
expression is unique to the C1 subgroup by cross-compar-
ing gene lists from different statistical tests. We first gen-
erated 2 different gene lists by applying 2-sample t tests
(P < 0.001). Gene list A represents the genes that were
differentially expressed between C1 and C2. Gene list B
represents the genes that were differentially expressed
between C2 and normal gastric tissues (Supplementary
Fig. S1). When gene expression patterns of all tissues were
compared together, 3 different patterns were observed: A
not B (2,755 genes), A and B (241 genes), and B not A
(1,437 genes). Genes in the A not B category displayed a
poor prognostic C1-specific gene expression pattern and
are potential markers for predicting RFS (Fig. 2). Because
the use of a complex algorithm with a long gene list from
microarray data may not be practical in the clinic, we tried
to identify a small number of genes whose expression
patterns can still reliably predict RFS. Of 2,755 genes in
A not B category, we further selected candidate genes on the
basis of ROC model analysis. Top 27 genes with highest
AUC values (14 genes) or lowest AUC values (13 genes)
were selected for validation with qRT-PCR experiments. We
next tested, using qRT-PCR, whether expression of these
genes or their subsets could predict the RFS in an inde-
pendent cohort (GSH1).
Six-gene signature and risk score
We again constructed another ROC models, using gene
expression data from qRT-PCR experiments with tissues
from GSH1 cohort, to assess the prognostic relevance of
gene expression in 96 GSH1 patients. Considering AUC
Table 1. Clinical characteristics of the patients
Characteristics YGC
(n ¼ 65)
GSH1
(n ¼ 96)
Age, y
Median 63 60
Range 32–83 26–77
% Sex
Male 46 (71%) 60 (62%)
Female 19 (29%) 36 (38%)
% Subsite of tumor
Cardia 5 (8%) 11 (12%)
Body 24 (37%) 47 (49%)
Antrum 31 (48%) 28 (29%)
Diffuse 4 (6%) 10 (10%)
Unknown 1 0
% Histologic type of tumor
Intestinal 23 (35%) 23 (24%)
Diffuse 32 (49%) 71 (74%)
Mixed 10 (16%) 2 (2%)
% Cancer stage, TNM class
I 12 (18.5%) 0 (0%)
II 2 (3%) 36 (38%)
III 34 (52%) 59 (61%)
IV 12 (18.5%) 1 (1%)
Relapse and survival
Relapse 27 (41%) 48 (50%)
Death 20 (30%) 33 (34%)
Adjuvant chemotherapy
Not received 16 (25%) 10 (10%)
Received 49 (75%) 86 (90%)
Cho et al.
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over 0.55 and under 0.45 to be significant, we found that
the expression of 6 genes (CTNNB1, EXOSC3, TOP2A,
LBA1, LZTR1, and CCL5) had a nontrivial correlation with
RFS. We next tested whether we could use expression of
these 6 genes as a prognostic signature in the GSH1 cohort.
When hierarchical clustering analysis was applied to the 6-
gene expression data, the 96 patients were divided into 2
subgroups with significantly different RFS (P ¼ 0.017 by
the log-rank test; Supplementary Fig. S2).
Because the use of hierarchical clustering analysis meth-
ods in clinical practice has proven to be difficult (24), we
developed risk score methods by using the Cox regression
coefficient of each gene (Supplementary Table S1; refs. 22,
23). Patients in the GSH1 cohort were dichotomized
according to their risk score, and the RFS rate was signifi-
cantly lower in the patient group with the high risk score
(P ¼ 0.048 by the log-rank test; Fig. 3). Gene expression
data from the YGC cohort were reanalyzed with the
6-gene–based risk score. With direct application of
the Cox regression coefficient from the GSH1 cohort and
the 50th percentile cutoff threshold, RFS in 2 patient
groups differed significantly (P ¼ 0.04 by the log-rank test;
Supplementary Fig. S3).
In the GSH1 cohort, the prognostic association between
our newly identified 6-gene signature and other known
clinical and pathologic risk factors for gastric cancer pro-
gression was assessed by univariate and multivariate ana-
lyses. As expectedly, in addition to stage and lymph node
status, which are already well-known risk factors, the
6-gene signature was a significant risk factor for shorter
RFS in univariate analysis (Table 2). Multivariate analysis
that included all relevant pathologic variables revealed that
Figure 1. Hierarchical clustering
analysis of gene expression data
from the YGC cohort. A,
hierarchical clustering of gene
expression data from 65 gastric
cancer and 6 GIST patients in the
YGC cohort. Genes with
expression levels that were at
least 2-fold different in at least 15
tissues, relative to the median
value across tissues, were
selected for hierarchical clustering
analysis (2,077 gene features). The
data are given in matrix format, in
which rows represent individual
genes and columns represent
each tissue. Each cell in the matrix
represents the expression level of
a gene feature in an individual
tissue. The color red or green in
cells reflects relative high or low
expression levels, respectively, as
indicated in the scale bar (log2-
transformed scale). B, Kaplan–
Meier plots of 3 gastric cancer
clusters in the YGC cohort. The 6
patients with GIST were excluded
from the plotting. C, Kaplan–Meier
plots of stage III patients in 2
clusters (C1 and C2) in the YGC
cohort. (No stage III patients were
identified in C3.)
Novel Prognostic Risk Score in Gastric Cancer
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the gene signature remained an independent prognostic
risk factor for RFS.
Validation of risk score in independent cohorts
We next sought to validate risk score in another inde-
pendent cohort, especially in stage III patients (GSH2
cohort, n ¼ 52; Supplementary Table S2). Expression data
of 6 genes from FFPE tissues were obtained by applying
qRT-PCR and used to generate risk score. When patients in
the GSH2 cohort were dichotomized according to their risk
score, both of RFS and overall survival rate were signifi-
cantly lower in the patient group with the high risk score
(P¼ 0.028 and P¼ 0.032, respectively, by the log-rank test;
Fig. 4A and D).
To test whether the 6-gene–based risk score is indepen-
dent of American Joint Committee on Cancer (AJCC) stage,
patients in GSH2 cohort were restratified according to
substage and risk score. As expected, prognosis of stage
IIIB is significantly worse than that of stage IIIA (Supple-
mentary Fig. S4A and C). When the risk score was applied
to stage IIIA and IIIB separately, the risk score successfully
identified a population of high-risk patients in both sub-
groups (Fig. 4B, C, E, and F). In fact, when all stratifications
were combined together, the risk score identified gastric
cancer patients in IIIA subgroup whose risk of relapse was
similar to or worse than that of IIIB (Supplementary
Fig. S4B and D). Because nodal stage is best known pre-
dictor of relapse, we assessed the utility of the risk score in
T3 patients who differed only with N stage (T3N1 and
T3N2). Nodal stage is well associated with RFS (Supple-
mentary Fig. S5A). Within these groups, the risk score
clearly identified high-risk patients (Supplementary
Fig. S5B–D). Taken together, these data indicate that the
risk score provides information on the risk of relapse
independent of current staging systems and shows that
the risk score captures biological differences among gastric
cancers that are not encompassed in the current staging
criteria.
Discussion
We identified and validated, using a series of indepen-
dent experiments and complementary data analyses
(Supplementary Fig. S6), robust prognostic markers in
gastric cancer and developed a prognostic risk score that
Figure 3. Risk score based on 6-gene signature and RFS of patients in
GSH1. A, the relative risk score based on the 6-gene signature of each
patient. (Each bar represents the risk score of an individual patient.) The
regression coefficients of each gene were calculated by Cox regression
analysis (Supplementary Table S1). The risk score was used to
dichotomize patients into high- or low-risk groups, with the 50th percentile
as the cutoff value. To avoid the ambiguity of a risk score near the median
value, patients in the top and bottom 5th percentiles from the risk score
median were removed from Kaplan–Meier plotting. Blank bars near the
median indicate these patients. B, Kaplan–Meier plots of 2 risk score risk
groups in the GSH1 cohort. P values were obtained from the log-rank test.
RS, risk score.
Figure 2.Gene expression signature unique to Cluster C1. Measured gene
expression values were log2-transformed and median-centered across
samples before generating heatmap.
Cho et al.
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can be easily translated into the clinic. First, we used
microarray technology to uncover potential prognostic
subgroups of gastric cancer patients and identify candidate
genes for prognostic markers. The association of gene
expression patterns with prognosis was significant
(Fig. 1), which suggests that our gene expression signature
well reflects clinical differences between subgroups of
patients with gastric cancer. However, the difficulty of
acquiring fresh-frozen tissues from patients and the com-
plexity of data analysis make it hard to use this approach in
the clinic. To overcome this limitation, we switched from
microarray-based technology to qRT-PCR technology, sim-
pler and easily accessible technology in clinics, to measure
gene expression and identified a small number of genes
(CTNNB1, EXOSC3, TOP2A, LBA1, LZTR1, and CCL5)
whose expression patterns can reliably predict the prog-
nosis of gastric cancer patients. The robustness of the
prognostic gene expression signature was validated in an
independent cohort by using the reduced gene set. For easy
translation of our finding to the clinic, we developed a risk
Figure 4. Kaplan–Meier survival
plots of overall survival and RFS in
AJCC stage III gastric cancer
patients in the GSH2 cohort.
Patients were stratified by risk
score in all stage III (A and D), risk
score in IIIA (B and E), in IIIB (C and
F). P values were obtained from
the log-rank test. RS, risk score.
Table 2. Univariate and multivariate Cox proportional hazard regression analyses of RFS
Univariate Multivariate
HR (95% CI) P HR (95% CI) P
Six-gene-based risk
score (high or low)
1.81 (0.998–3.3) 0.0476 2.587 (1.351–4.953) 0.004
T (T2 or T3) 4.42 (2.21–8.81) <0.001 3.969 (1.906–8.265) <0.001
N (N1 or N2) 2.94 (1.65–5.22) <0.001 3.389 (1.686–6.815) <0.001
Age (>60 or not) 0.652 (0.368–1.16) 0.140 0.701 (0.354–1.390) 0.31
Gender (M or F) 0.56 (0.317–0.991) 0.043 0.567 (0.306–1.059) 0.075
Adjuvant chemotherapy (yes or no) 0.423 (0.189–0.947) 0.031 0.358 (0.142–0.904) 0.03
Lauren classification (intestinal or diffuse) 0.935 (0.475–1.84) 0.844 1.384 (0.612–3.131) 0.44
Novel Prognostic Risk Score in Gastric Cancer
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score for relapse after curative resection of tumor (Fig. 3).
Finally, the robustness of our risk score was validated in an
independent cohort, especially in stage III patients who
show most heterogeneous clinical outcome (Fig. 4 and
Supplementary Fig. S5).
The uniquemolecular characteristics of each subgroup of
gastric cancer may lead to new therapeutic strategies.
CTNNB1 is a key mediator of the WNT signaling pathway
that regulates cell-fate decisions and cell proliferation dur-
ing gut development (25). Activated mutation of CTNNB1
was reported in gastric cancer, and abnormal expression of
CTNNB1 in gastric cancer was significantly associated with
poorer survival (26, 27), supporting the notion that our
gene expression data may well recapitulate the molecular
abnormality of gastric carcinogenesis. TOP2A encodes a
DNA topoisomerase II, an enzyme that controls the topo-
logic state of DNA during transcription. This gene is cur-
rently the target of several anticancer agents, and a variety of
its mutations have been associated with the development
of drug resistance (28–30).
The development of the 6-gene–based risk score has
strong clinical implications. We could identify gastric can-
cer patients at higher risk by using simple qRT-PCR tech-
nology and paraffin-embedded tissues, which are routinely
acquired at diagnosis. One of limitations of our study is its
retrospective character. Thus, to validate its true clinical
relevance of the risk score, it will be necessary that 6-gene–
based risk score is integrated into prospective randomized
trials in the form of a biologic stratification criterion. In
addition, because this new approach has not been applied
to samples from small pretreatment biopsies, the reliability
of the new approach should be extensively tested before its
use in clinical trials.
Prognostic characteristics of the risk score may not be
sufficient to change current clinical practice because they
provide only information on probable course of the disease
and not the probable response to treatments. However,
biomarker study in breast cancer showed that 21-gene
prognostic marker could also be used as predictive marker
for standard adjuvant chemotherapy (23). Thus, in future
study, it will be interesting to test whether the risk score can
also be good predictive marker for response to adjuvant
chemotherapy.
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